Liste des publications BETPSY
Projet BETPSY
Biomarkers in autoimmune EncephaliTis and
Paraneoplastic neurological SYndromes
Articles Scientifiques
Campetella et al. Predictors and Clinical Characteristics of Relapses in LGI1-Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2024 . doi: 10.1212/NXI.0000000000200228. (WP2)
Farina et al. Mononeuritis multiplex following immune checkpoint inhibitors in malignant pleural mesothelioma. Frontiers. 2024. https://doi.org/10.3389/fneur.2024.1338899 (WP2)
Villagran-Garcia et al. Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis. Brain Commun. 2023. 10.1093/braincomms/fcad247 (WP2)
Farina A. et al. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity, Brain Communications, Volume 5, Issue 3, 2023, fcad169, https://doi.org/10.1093/braincomms/fcad169 (WP2)
Bartley C. et al. Detection of High-Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins. Ann Neurol. 2023. doi: 10.1002/ana.26776 (WP2)
Theuriet J. et al. Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease. J Neurol. 2023 ;270(11):5545-5560. doi: 10.1007/s00415-023-11908-7 (WP2)
Vogrig et al. Different Genetic Signatures of Small-Cell Lung Cancer Characterize Anti-GABABR and Anti-Hu Paraneoplastic Neurological Syndromese. Ann Neurol. 2023. https://doi.org/10.1002/ana.26784. (WP4)
Cluse F et al. Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease. Neurol Neuroimmunol Neuroinflamm. 2023 . doi: 10.1212/NXI.0000000000200153. (WP2)
Alentorn A et al. Spatial and Ecological Factors Modulate the Incidence of Anti-NMDAR Encephalitis—A Systematic Review. Neurol Neuroimmunol Biomedecine. 2023. https://doi.org/10.3390/biomedicines11061525. (WP2)
Schiff P et al.. Anti-LGI1 Encephalitis With Co-occurring IgLON5 Antibodies: Clinical Features and Human Leukocyte Antigen Haplotypes. Neurol Neuroimmunol Neuroinflamm. 2023. doi: 10.1212/NXI.0000000000200126. (WP2)
Ciano-Petersen NL et al. Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2023. doi: 10.1212/NXI.0000000000200108. (WP2)
Vilaseca, A.et al. The expanding spectrum of antibody-associated cerebellar ataxia: report of two new cases of anti-AP3B2 ataxia. J Neurol. 2023. https://doi.org/10.1007/s00415-023-11732-z (WP2)
Flet-Berliac., et al. Long-term outcome of paediatric anti-N-methyl-D-aspartate receptor encephalitis. Develomental medicine & child neurology 2023. https://doi.org/10.1111/dmcn.15429 (WP2)
Faure F., et al. A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model. The Cerebellum 2023. https://doi.org/10.1007/s12311-023-01524-6 (WP2)
Khatib L., et al. Autoimmune Cerebellar Ataxia Associated withAnti‑Glutamate Receptor δ2 Antibodies: a Rare but Treatable Entity. The Cerebellum. 2023. https://doi.org/10.1007/s12311-023-01523-7 (WP2)
Farina A., et al. Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors. Neurol Neuroimmunol Neuroinflamm. 2023. DOI: https://doi.org/10.1212/NXI.0000000000200058 (WP2)
Vabanesi M., et al. SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques. Journal of neurology. 2023. 10.1007/s00415-022-11523-y (WP2)
Benoit J, et al. Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis Clues for Diagnosis. Neurol Neuroimmunol Neuroinflamm. 2022. https://doi.org/10.1212/NXI.0000000000200041 (WP2)
Moritz C, and al. Conformation-stabilizing ELISA and cell-based assays reveal patient subgroups targeting three different epitopes of AGO1 antibodies. Front. Immunol. 2022. https://doi.org/10.3389/fimmu.2022.972161 (WP2)
Villagran-Garcia M et al. Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review. J Neurol. 2022. doi: 10.1007/s00415-022-11356-9 (WP2)
Peter E, Do LD, et al. Cerebellar Ataxia With Anti-DNER Antibodies: Outcomes and Immunologic Features. Neurol Neuroimmunol Neuroinflamm. 2022. doi: 10.1212/NXI.0000000000200018 (WP2)
Peter E, Treilleux I, et al. Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration. Neurol Neuroimmunol Neuroinflamm. 2022. 10.1212/NXI.0000000000200015 (WP4)
Peris Sempre V, Muñiz-Castrillo S, et al. Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2022. DOI: https://doi.org/10.1212/NXI.0000000000001140 (WP3)
Lardeux P, et al. Core cerebrospinal fuid biomarker profile in anti‑LGI1 encephalitis. Journal of neurology. 2022. https://doi.org/10.1007/s00415-021-10642-2 (WP2)
Tholance Y, Antoine JC, et al. Anti-FGFR3 antibody epitopes are functional sites and correlate with the neuropathy pattern. Journal of neuroimmunology. 2021. https://doi.org/10.1007/s00415-021-10870-6 (WP2)
Vogrig A, Péricart S, et al. Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis. Brain Communications. 2021. https://doi.org/10.1093/braincomms/fcab185 (WP2)
Do L, Moritz C, and et. Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases. Neurol Neuroimmunol Neuroinflamm. 2021. DOI: https://doi.org/10.1212/NXI.0000000000001032 (WP2)
Muñiz-Castrillo S, Hedou J, et al. Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. Brain, 2021; awab153, https://doi.org/10.1093/brain/awab153 (WP3)
Muñiz‑Castrillo S, Haesebaert J et al. Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021. DOI: https://doi.org/10.1212/NXI.0000000000000974 (WP3)
Muñiz‑Castrillo S, Vogrig A et al. Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study. Journal of neurology. 2021. https://doi.org/10.1007/s00415-021-10424-w (WP3)
Moritz C, et al. CIDP Antibodies Target Junction Proteins and Identify Patient Subgroups. Neurol Neuroimmunol Neuroinflamm. 2021. doi.org/10.1212/NXI.0000000000000944 (WP2)
Vogrig A, et al. Cranial Nerve Disorders Associated with Immune Checkpoint Inhibitors. Neurology. 2020. doi.org/10.1212/WNL.0000000000011340 (WP2)
Moritz C et al. Proper definition of the set of autoantibody-targeted antigens relies on appropriate reference group selection. New biotechnology. 2020. doi.org/10.1016/j.nbt.2020.08.007 (WP2)
Hébert J, Riche B et al. Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm. 2020; 7 (6). https://doi.org/10.1212/NXI.0000000000000883 (WP1-WP6)
Muñiz‑Castrillo S, Joubert B, et al. Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features. J Neurol Neurosurg Psychiatry. 2020; 0:1–9. doi.org/10.1136/jnnp-2020-323226 (WP3)
Muñiz‑Castrillo S, Vogrig A, Joubert B, and al. Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies. Cerebellum. 2020; 19 715-721. https://doi.org/10.1007/s12311-020-01159-x (WP2)
Vogrig A, Muñiz‑Castrillo S, Joubert B, et al. Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry. 2020; 91:772-778. doi: 10.1136/jnnp-2020-323212 (WP2)
Simard C, Vogrig A, Joubert B, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm. 2020; 7:e699. DOI: https://doi.org/10.1212/NXI.0000000000000699 (WP2)
Déchelotte B, Muñiz‑Castrillo S, Joubert B, et al. Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurological syndromes. Neurol Neuroimmunol Neuroinflamm. 2020; 7(3):e701. https://doi.org/10.1212/NXI.0000000000000701 (WP2)
Muñiz‑Castrillo S, Ambati A, Dubois V, et al. Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies. J Neurol. 2020; 267:1906-1911. http://dx.doi.org/10.1007/s00415-020-09782-8 (WP3)
Vogrig. A, Gigli, G.L., Segatti, S. et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol. 2020; 267: 26-35. http://dx.doi.org/10.1007/s00415-019-09544-1 (WP2)
Joubert, B., Belbezier, A., Haesebaert, J. et al. Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies. J Neurology. 2020. https://doi.org/10.1007/s00415-020-09807-2 (WP2)
Revues
Muñiz-Castrillo, Sergio et al. Genetic predisposition to autoimmune encephalitis and paraneoplastic neurological syndromes. Current Opinion in Neurology. 2024 DOI: 10.1097/WCO.0000000000001263 (WP3)
Farina A et al. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol. 2024; 23: 81–94. doi.10.1016/S1474-4422(23)00369-1.(WP2)
Vogrig et al. Sudden unexpected death in epilepsy and ictal asystole in patients with autoimmune encephalitis: a systematic review. Neurological Sciences. 2024. https://doi.org/10.1007/s10072-023-07280-z (WP2)
Villagrán-García M et al. Autonomic nervous system involvement in autoimmune encephalitis and paraneoplastic neurological syndromes. Rev Neurol. 2023. doi: 10.1016/j.neurol.2023.12.001 (WP2)
Farina A et al. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management. Revue neurologique. 2023. https://doi.org/10.1016/j.neurol.2023.03.003 (WP2)
Campérat L et al. Autoimmune neuromyotonia. Curr Opin Neurol. 2022. 10.1097/WCO.0000000000001104. (WP2)
Antoine JC. Sensory neuronopathies, diagnostic criteria et causes. Curr Opin Neurol. 2022. Volume 4, Issue 4, 2022, fcac196, 10.1097/WCO.0000000000001105. (WP2)
Ciano-Petersen NL et al. Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis. Brain communications. 2022. Volume 4, Issue 4, 2022, fcac196, https://doi.org/10.1093/braincomms/fcac196 (WP2)
Vaišvilas M, Ciano-Petersen NL, et al. Paraneoplastic encephalitis: clinically based approach on diagnosis and management. Postgrad Med J. 2022 -141766. doi: 10.1136/postgradmedj-2022-141766 (WP2)
Muñiz‑Castrillo S, Vogrig A, et al. Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses. The Cerebellum. 2022.https://doi.org/10.1007/s12311-021-01363-3 (WP2)
Ciano-Petersen N, Muñiz‑Castrillo S, et al. Immunomodulation in the acute phase of autoimmune encephalitis. Revue neurologique. 2022. https://doi.org/10.1016/j.neurol.2021.12.001 (WP2)
Ciano-Petersen N et al. Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Int J Mol Sci. 2021. doi: 10.3390/ijms222313127 (WP2)
Binks S, Uy C, Honnorat J, Irani S. Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Pract Neurol. 2021. http://dx.doi.org/10.1136/practneurol-2021-003073 (WP2)
Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021. DOI: 10.1212/NXI.0000000000001014 (WP2)
Vogrig A, Muñiz-Castrillo S, et al. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update. Journal of neurology. 2021. https://doi.org/10.1007/s00415-021-10870-6 (WP2)
Fels E, Muñiz‑Castrillo S, et al. Role of LGI1 protein in synaptic transmission: From physiology to pathology. Neurobiology of disease. 2021. doi: 10.1016/j.nbd.2021.105537 (WP2)
Wiendl H, Gross C, et al. Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases: A Systematic Review. Nature Reviews Neurology 2021. https://doi.org/10.1038/s41582-021-00496-7 (WP5)
Marini A, Bernardini A, et al. Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Neurology 2021. DOI: https://doi.org/10.1212/WNL.0000000000011795 (WP2)
